Glacier FarmMedia COVID-19 & the Farm

China approves Syngenta’s Viptera corn: reports

Chicago | Reuters — Chinese authorities have informed some agriculture industry officials that the government has approved U.S. imports of a type of genetically modified corn that has sparked lawsuits against seed maker Syngenta, according to reports from Agri-Pulse and Bloomberg.

Syngenta will make an announcement about Chinese government approval of Agrisure Viptera corn, known as MIR 162, when the company receives official documentation, a spokesman said in an email. The company said Friday it was expecting China to clear imports soon.

Traders are watching the U.S.-China Joint Commission on Commerce and Trade in Chicago for news about MIR 162 approval. U.S. Agriculture Secretary Tom Vilsack is expected to discuss barriers to imports of U.S. genetically modified crops at the forum, which runs from Tuesday to Thursday.

Beijing has rejected shipments of more than one million tonnes of U.S. crops in the past year because they contained traces of MIR 162 corn.

Global grain handlers Cargill and Archer Daniels Midland, along with dozens of U.S. farmers, have sued Syngenta for damages from the rejections. They claim the seed company misled the farm industry about the timeline for approval by China, a major importer.

Expectations for China to approve imports of MIR 162 corn helped lift U.S. corn futures to five-month highs on Monday. Most-active March corn was near unchanged on Tuesday at $4.09 a bushel.

Approval could lift U.S. corn exports, traders said. In Ukraine, a rival exporter, state grain firm GPZKU on Tuesday confirmed there were disruptions in corn intended for China.

— Reporting for Reuters by Mark Weinraub and Tom Polansek in Chicago.

Tagged , ,
COPA Medallion COPA finalist in 2012, 2014 and 2015.
©2021 AGCanada is a production of Glacier FarmMedia Limited Partnership. Any affiliated or third party content is the property of its respective owner and is used with permission.
Please refer to Copyright Page for details.
Click here to view our Website Terms of Use.